TY - JOUR
TI - Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: An international audit
AU - Semb, A.G.
AU - Rollefstad, S.
AU - Ikdahl, E.
AU - Wibetoe, G.
AU - Sexton, J.
AU - Crowson, C.
AU - Van Riel, P.
AU - Kitas, G.
AU - Graham, I.
AU - Rantapää-Dahlqvist, S.
AU - Karpouzas, G.A.
AU - Myasoedova, E.
AU - Gonzalez-Gay, M.A.
AU - Sfikakis, P.P.
AU - Tektonidou, M.G.G.
AU - Lazarini, A.
AU - Vassilopoulos, D.
AU - Kuriya, B.
AU - Hitchon, C.
AU - Stoenoiu, M.S.
AU - Durez, P.
AU - Pascual-Ramos, V.
AU - Galarza-Delgado, D.A.
AU - Faggiano, P.
AU - Misra, D.P.
AU - Borg, A.A.
AU - Mu, R.
AU - Mirrakhimov, E.M.
AU - Gheta, D.
AU - Douglas, K.
AU - Agarwal, V.
AU - Myasoedova, S.
AU - Krougly, L.
AU - Valentinovna Popkova, T.
AU - TuchyÅ ová, A.
AU - Tomcik, M.
AU - Vrablik, M.
AU - Lastuvka, J.
AU - Horak, P.
AU - Medkova, H.K.
AU - Kerola, A.M.
JO - RMD Open: Rheumatic & Musculoskeletal Diseases
PY - 2021
VL - 7
TODO - 2
SP - null
PB - BMJ Publishing Group
SN - 2056-5933
TODO - 10.1136/rmdopen-2021-001724
TODO - cardiovascular disease;  complication;  diabetes mellitus;  human;  rheumatoid arthritis;  risk factor, Arthritis, Rheumatoid;  Cardiovascular Diseases;  Diabetes Mellitus;  Heart Disease Risk Factors;  Humans;  Risk Factors
TODO - Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014-2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA. ©
ER -